AD-2022
N/A
Report date: 2024/07/18 11:10:52
NME
Base Information
Drug NameAD-2022
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesAddpharma Inc
China Registration ClassN/A
Develop Information
Other Information
ATC CodeN/A
Related LinksN/A